MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)

Wei-feng Sun; Xian-xian Zhang; Fen-yong Sun; Wei Xu; Jing Liang; Shu-mei Feng; Tian Wang

doi:10.1007/s11655-011-0605-6

Your Location：

Home >

Browse articles >

MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)

Updated：2021-08-27

- MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)
- Chinese Journal of Integrative Medicine Vol. 17, Issue 1, Pages: 35-42(2011)
- Affiliations：
  
  1. Department of Traditional Chinese Medicine, General Hospital of Guangzhou Military Command of PLA,Guangzhou,China
  2. Institute of Bioengineering, Jinan University,Guangzhou,China
- Author bio：
- Funds：
  
  Supported by the National Natural Science Foundation of China (No. 81072915);Military Eleventh-Five-Year Tackle Key Program in Science and Technology (No. 2006062004)
- DOI：10.1007/s11655-011-0605-6
  CLC：
- Published：2011，
  
  Published Online：22 January 2011，
Scan for full text
Sun, Wf., Zhang, Xx., Sun, Fy. et al. MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)., Chin. J. Integr. Med. 17, 35–42 (2011). https://doi.org/10.1007/s11655-011-0605-6

Wei-feng Sun, Xian-xian Zhang, Fen-yong Sun, et al. MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方). [J]. Chinese Journal of Integrative Medicine 17(1):35-42(2011)
Sun, Wf., Zhang, Xx., Sun, Fy. et al. MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方)., Chin. J. Integr. Med. 17, 35–42 (2011). https://doi.org/10.1007/s11655-011-0605-6 DOI：

Wei-feng Sun, Xian-xian Zhang, Fen-yong Sun, et al. MicroRNA expression patterns of the kidney in hyperuricemia mice treated with Xiezhuo Chubi Decoction (泄浊除痹方). [J]. Chinese Journal of Integrative Medicine 17(1):35-42(2011) DOI： 10.1007/s11655-011-0605-6.

摘要

To investigate the effects of Xiezhuo Chubi Decoction (泄浊除痹方

XZCBD) on the microRNA expression patterns of kidney in mice with hyperuricemia. Sixty Kunming male mice were randomly divided into the high-

medium-

and low-dose XZCBD groups

benzbromarone group

model group

and control group. Except the control group

all mice were established with yeast method combined with uricase inhibition method to build hyperuricemia model

and the corresponding drugs (37.5 g/kg

18.75 g/kg

9.375 g/kg

and 0.02 g/kg per day) were administrated on the 7th day. On the 22nd day

the blood uric acid concentration was detected

and microRNA with obvious changes in kidney was screened with qRT-PCR. The uric acid in the model group was higher than that in the control group

and the levels of the uric acid were reduced after being treated with XZCBD; the differences among groups were signifificant (P<0.05). Compared with the control group

32 kinds of microRNA expression changes were detected on the 15th day after being treated with high-dose XZCBD by microRNA expression profifile screening. Among them

miR-34a could inhibit the expression of human urate anion exthanger 1

and miR-146a might have inhibited the inflflammatory reaction. XZCBD could significantly reduce the serum uric acid level; its effect on hyperuricemia might be through affecting microRNA expressions.

Abstract

To investigate the effects of Xiezhuo Chubi Decoction (泄浊除痹方

XZCBD) on the microRNA expression patterns of kidney in mice with hyperuricemia. Sixty Kunming male mice were randomly divided into the high-

medium-

and low-dose XZCBD groups

benzbromarone group

model group

and control group. Except the control group

all mice were established with yeast method combined with uricase inhibition method to build hyperuricemia model

and the corresponding drugs (37.5 g/kg

18.75 g/kg

9.375 g/kg

and 0.02 g/kg per day) were administrated on the 7th day. On the 22nd day

the blood uric acid concentration was detected

and microRNA with obvious changes in kidney was screened with qRT-PCR. The uric acid in the model group was higher than that in the control group

and the levels of the uric acid were reduced after being treated with XZCBD; the differences among groups were signifificant (P<0.05). Compared with the control group

32 kinds of microRNA expression changes were detected on the 15th day after being treated with high-dose XZCBD by microRNA expression profifile screening. Among them

miR-34a could inhibit the expression of human urate anion exthanger 1

and miR-146a might have inhibited the inflflammatory reaction. XZCBD could significantly reduce the serum uric acid level; its effect on hyperuricemia might be through affecting microRNA expressions.

关键词

hyperuricemiakidneymicroRNAshuman urate anion exthanger 1

Keywords

hyperuricemiakidneymicroRNAshuman urate anion exthanger 1

references

Wang F. Research progress for urate transporters in renal. Section Endocrinol Foreign Med Sci 2004;24:388–390.

Hong Q, Wu D, Chen XM, Hou K, Feng Z, Fu B, et al. Location and expression of human uric acid transporter in HKC. Chin J Nephrol (Chin) 2005;21:527–533.

Yan HY, Zhou LL. Research progress for effect of uric acid transport protein nuric acid transporter. China Pharmacy (Chin) 2007;18:1108–1110.

Cheong HI, Kang JH, Lee JH, Ha IS, Kim S, Komoda F, et al. Mutational analysis of idiopathic renal hypouricemia in Korea. Pediatr Nephrol 2005;20:886–890.

Sun WF, Zhang XX, Xu W. Therapeutic effect of two compositions of Xiezhuo Chubi Decoction on primary gout hyperuricemia. Milit Med J of South China (Chin) 2009;23:35.

Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15–20.

Wu LG, Fan JH, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006;103:4034–4039.

Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 2007;210:279–289.

Chen GL, Xu SY. Research progress for animal hyperuricemia model. Chin Pharmacol Bull (Chin) 2004;20:369–372.

Qin XC. Effects of iptakalim on hypertension and renal injury induced by hyperuricemia and its protective effects on the endothelial function. Beijing: PLA Postgraduate Medical School; 2006:14–18.

Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008;19:3272–3282.

Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980–984.

Torcia MG, Santarlasci V, Cosmi L, Clemente A, Maggi L, Mangano VD, et al. Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria. Proc Natl Acad Sci USA 2008;105:646–651.

Tilton JC, Manion MM, Luskin MR, Johnson AJ, Patamawenu AA, Hallahan CW, et al. Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro. J Virol 2008;82:3997–4006.

Tong GH, Zhang Y, Ma L. Research progress for hyperuricemia model of rodent animal. J Toxicol 2009; 23:159–162.

Chen GL, Xu XY. Research progress for animal hyperuricemia model. Chin Pharmacol Bull 2004;20:369–372.

Tang C, Yang K. A preliminary study on the Establishment of animal model with hyperuricemia. Tradi Chin Drug Res Clin Pharmacol (Chin) 2000;11:292–295.

Chen GL, Zhang QL, Ma XQ, Xu SY. Hyperuricemia model induced by yeast in mice. Chin Pharmacol Bull (Chin) 2003;19:467–469.

Yan HY, Ma Y, Liu M, Zhou LL. Effect of extracts of paederia scandens on mouse hyperuricemia induced by yeast and potassium oxonate. Acta Univ Med Anhui (Chin) 2007;42:676–678.

Tan WC, Tang JY, Zhang Y, Yang WX. The research of the function mechanism of anti-hyperuricuria through warming kidney and removing blood Stasis. Lishizhen Med Mat Med Res (Chin) 2006;17:11–13.

Gao BZ, Li YP, Li CD, Wu TY, Zheng LP. Effect of different TCM prescriptions on XOD & renal function in rats with hyperuricemia. China J Tradit Chin Med Pharm (Chin) 2008;23:97–99.

Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K, Sonoyama K, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertension 2008;21:1157–1162.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The theory of homogeny of liver and kidney in the treatment of kidney and liver fibrosis

Effects ofRheum officinale on the renal hypertrophy and hyperfiltration in the streptozotocin-induced diabetic rats

Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia

Role of heteroplasmic mutations in the mitochondrial genome and the ID4 gene promoter methylation region in the pathogenesis of chronic aplastic anemia in patients suffering from Kidney yin deficiency

Compound Tufuling Granules (复方土茯苓颗粒) regulate glucose transporter 9 expression in kidney to influence serum uric acid level in hyperuricemia mice

Related Author

No data

Related Institution

Department of Pharmacology, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital

Institute of Nephrology, Jinling Hospital

College of Traditional Chinese Medicine, Guangdong Pharmaceutical University

Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Postdoctoral Research Station, Shandong University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰